A - Human Necessities – 61 – K
Patent
A - Human Necessities
61
K
A61K 31/56 (2006.01) A61K 31/565 (2006.01) A61K 31/568 (2006.01) A61P 27/02 (2006.01) C07J 73/00 (2006.01) A61K 38/00 (2006.01)
Patent
CA 2367643
The topical application, at a dose rate less than or equal to 0.1 mg day, to the ocular surface or adjacent regions of the eye of a preparation containing a therapeutically effective amount of an androgen or androgen analogue or a therapeutically effective amount of TGF-.beta. is disclosed as a method of relieving the chronic and acute manifestation of dry eye signs and symptoms in keratoconjunctivitis sicca (KCS), for example in Sjögren's syndrome.
L'invention concerne une méthode qui consiste à appliquer localement, sur la surface oculaire ou sur des zones adjacentes de l'oeil, à un débit de dose inférieur ou égal à 0,1 mg/jour, une préparation renfermant une dose thérapeutiquement efficace d'androgènes ou d'analogues d'androgènes ou une dose thérapeutiquement efficace du facteur de croissance transformant bêta (TGF-.beta.), de manière à soulager les manifestations chronique et aiguë des signes et symptômes d'oeil sec dans la kératoconjonctivite sèche, notamment dans le cas du syndrome de Sjögren.
Ridout & Maybee Llp
The Schepens Eye Research Institute Inc.
LandOfFree
Ocular therapy in keratoconjuctivitis sicca using topically... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Ocular therapy in keratoconjuctivitis sicca using topically..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Ocular therapy in keratoconjuctivitis sicca using topically... will most certainly appreciate the feedback.
Profile ID: LFCA-PAI-O-1924676